⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Official Title: A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Study ID: NCT02771626

Interventions

CB-839
Nivolumab

Study Description

Brief Summary: This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Honor Health, Scottsdale, Arizona, United States

Stanford University, Palo Alto, California, United States

University of Colorado, Aurora, Colorado, United States

University Cancer Blood Center, Athens, Georgia, United States

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Massachusetts General Hospital, Boston, Massachusetts, United States

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Karmanos Caner Center, Detroit, Michigan, United States

New York University, New York, New York, United States

Columbia University Medical Center, New York, New York, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

University Hospitals Cleveland, Cleveland, Ohio, United States

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Vanderbilt University, Nashville, Tennessee, United States

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Seattle Cancer Care Alliance/University of Washington, Seattle, Washington, United States

Northwest Medical Specialties, Tacoma, Washington, United States

Contact Details

Name: Sam Whiting, MD, PhD

Affiliation: Calithera Biosciences, Inc

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: